The global smart pills market is a rapidly growing sector within the healthcare industry. Smart pills, equipped with sensors and wireless technology, offer real-time monitoring, diagnosis, and targeted drug delivery. They improve patient compliance, enable personalized medicine, and facilitate remote patient monitoring. With technological advancements and the increasing prevalence of chronic diseases, the market is driven by factors such as improved healthcare outcomes, cost-effectiveness, and the demand for non-invasive healthcare solutions.
Get Free Sample Report: https://databridgemarketresearch.com/reports/global-smart-pills-market
Data Bridge Market Research analyses that the Smart Pills Market is expected to grow at a value of USD 14.42 billion by 2029, with a CAGR of around 16.71% during the forecast period from 2022 to 2029 from USD 4.19 billion in 2021. Smart pills allow for real-time monitoring of the gastrointestinal tract and provide valuable data to healthcare providers. This enables remote patient care, as healthcare professionals can review the captured images and data to make accurate diagnoses and treatment decisions. The increasing demand for remote monitoring and telemedicine services is driving the adoption of smart pills.
Key Findings of the Study
Focus on personalized medicine is expected to drive the market's growth rate
Smart pills play a crucial role in enabling personalized medicine by providing real-time data on patient medication response. This data helps healthcare providers tailor treatment plans and optimize therapy based on individual patient needs. Monitoring factors such as drug absorption, adherence, and physiological response, smart pills enable adjustments in dosages and treatment regimens. This personalized approach improves treatment effectiveness, minimizes side effects, and enhances patient outcomes, ultimately leading to more precise and targeted healthcare interventions.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014-2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Multi parameter Monitoring, Single Parameter Monitoring), Disease Indication (Occult GI Bleeding, Crohn’s Disease, Small Bowel Tumors, Celiac Disease, Inherited Polyposis Syndromes, Mental Disorders), Application (Capsule Endoscopy, Drug Delivery, Patient Monitoring of Cancer), End User (Hospital, Diagnostic Centers, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
ACAMP (Canada), BDD Ltd (South Korea), Boston Scientific Corporation (U.S.),Cerner Corporation (U.S.),FUJIFILM Holdings Corporation (Japan), GENERAL ELECTRIC COMPANY (U.S.), MEDTRONIC (Ireland), Olympus Corporation (Japan), PENTAX Medical (Japan), Proteus Digital Health (U.S.) among others
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis:
The smart pills market is segmented on the basis of type, disease indication, application, and end user
- On the basis of type, the smart pills market is segmented into multi parameter monitoring and single parameter monitoring. Multipara meter monitoring segment dominates due to its ability to measure multiple parameters simultaneously, providing comprehensive and real-time data for various applications. This allows for a more comprehensive understanding of the monitored system compared to single parameter monitoring in the forecast period of 2022-2029.
- On the basis of disease indication, the smart pills market is segmented into occult GI bleeding, Crohn’s disease, small bowel tumors, celiac disease, inherited polyposis syndromes and mental disorders. Occult GI bleeding holds dominance in disease indication due to its significance as a hidden source of gastrointestinal bleeding that requires accurate diagnosis and monitoring. Capsule endoscopy is commonly used to detect and evaluate occult GI bleeding, contributing to its dominance in the forecast period of 2022-2029.
- On the basis of application, the smart pills market is segmented into capsule endoscopy, drug delivery, and patient monitoring of cancer. The capsule endoscopy segment dominates the application segment of the market due to its non-invasive nature and ability to provide comprehensive visualization of the gastrointestinal tract, aiding in the diagnosis and monitoring of various digestive disorders and diseases in the forecast period of 2022-2029.
In 2022, the capsule endoscopy segment dominates the application segment of the market
In 2022, the capsule endoscopy segment dominates the application segment of the market owing to its non-invasive nature, ability to capture detailed images of the gastrointestinal tract, and its widespread use for diagnosing gastrointestinal disorders in the forecast period of 2022-2029.
- On the basis of end user, the smart pills market is segmented into hospital, diagnostic centers and others. The hospital segment dominates the end user segment of the market due to their primary role in providing healthcare and their extensive use of cutting-edge diagnostic tools for patient care and monitoring in the forecast period of 2022 to 2029.
In 2022, the hospital segment dominates the end user segment of the market
In 2022, the hospital segment dominates the end user segment of the market owing to their role as primary healthcare providers and their extensive use of advanced diagnostic technologies for patient care and monitoring purposes in the forecast period of 2022 to 2029.
Major Players
Data Bridge Market Research recognizes the following companies as the major smart pills market players in smart pills market are Cerner Corporation (U.S.), FUJIFILM Holdings Corporation (Japan), GENERAL ELECTRIC COMPANY (U.S.), MEDTRONIC (Ireland), Olympus Corporation (Japan), PENTAX Medical (Japan)
Market Development
- In 2023, The NaviCam Small Bowel System was introduced by AnX Robotica Corp. (US) in that country. The NaviCam SB System makes use of aspherical lens technology to improve the field of vision and lessen distortion, which is essential for the diagnosis of small bowel disease.
- In 2021, The PillCam Small Bowel 3 system has received 510(k) clearance from the US FDA for use in remote endoscopy procedures.
- In 2021, Check-Cap (Israel) improved technical issues from a single source supplier while also increasing C-Scan's manufacturing capacity and on-site production line. To support its U.S. pivotal study, the company significantly expanded its production line.
- In 2020, The FDA has granted De-Novo classification to AnX Robotica Corp. (US) for its NaviCam Magnetically Controlled Capsule Endoscopy (MCCE) System. It is a groundbreaking system that enables full, real-time visualization of the stomach using a pill-sized capsule that contains a camera and is remotely controlled by the doctor using advanced magnetic technologies.
- In 2020, The International Standard Organization (ISO) 27001 security certification was earned by CapsoVision Inc. (U.S.). The certification covers CapsoVision's corporate offices as well as its CapsoCloud software. The company's long-term dedication to the protection of customer data is validated by this certification.
Regional Analysis
Geographically, the countries covered in the smart pills market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
As per Data Bridge Market Research analysis:
North America is the dominant region in smart pills market during the forecast period 2022 to 2029
North America's dominance in the smart pills market can be attributed to its advanced technological developments in the healthcare sector. The region has witnessed significant progress in the development and adoption of smart pill technologies. Additionally, the rising incidence of colorectal cancer and the regulatory approval of new smart pill products contribute to the market's growth. These factors create a favorable environment for the expansion of the smart pills market in North America during the forecast period.
Asia-Pacific is estimated to be the fastest growing region in smart pills market the forecast period 2022 to 2029
The Asia-Pacific region is expected to experience substantial growth in the smart pills market due to the implementation of compulsory healthcare insurance in several countries. With the expansion of healthcare coverage, more individuals have access to medical services and treatments, including smart pills. This increased access to healthcare resources and insurance coverage drives the demand for innovative healthcare technologies, such as smart pills, leading to significant market growth in the Asia-Pacific region.
For more detailed information about the smart pills market report, click here – https://www.databridgemarketresearch.com/pt/reports/global-smart-pills-market
